Pentoxifylline, progression of chronic kidney disease (CKD) and cardiovascular mortality: long-term follow-up of a randomized clinical trial

Morales, Alejandra Muñoz de; Goicoechea, Marián; Verde, Eduardo; Carbayo, Javier; Barbieri, Diego; Delgado, Andrés; Verdalles, Úrsula; José, Ana Pérez de; Luño, José

doi:10.1007/s40620-019-00607-0

Cited by 20 publications

(15 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[10] Pemberian terapi jangka panjang dengan PTX juga menunjukkan efek penurunan terhadap risiko kardiovaskular. [11] Melihat pengobatan konvensional yang saat ini digunakan untuk menangani CKD masih belum memberikan efek yang efekif dan dapat menimbulkan efek jangka panjang, seperti risiko terhadap mortalitas kardiovaskular, maka sangat diperlukan pengobatan adjuvan dalam penanganan CKD. Beberapa studi berhasil menunjukkan bahwa PTX berpotensi sebagai terapi adjuvan untuk membantu dalam mencegah dan menghambat progresivitas CKD.…”

Section: Pendahuluanunclassified

“…Sitokin yang disintesis, seperti monocyte chemoattractan protein-1 (MCP-1), interleukin 1 (IL-1), interleukin 6 (IL-6), dan tumor necrosis factor alpha (TNF-α). [11,20,21,22] Dalam studi yang dilakukan oleh Juan et al (2018), dinyatakan bahwa pemberian terapi PTX pada penderita CKD dapat meningkatkan konsentrasi dari klotho serum dan urin. Temuan tersebut juga didukung oleh hasil penelitian yang menunjukkan bahwa PTX mencegah timbulnya down-regulasi dari ekspresi klotho protein dan messenger RNA (mRNA).…”

Section: Artikel Tinjauan Pustakaunclassified

“…PTX dinyatakan dapat menurunkan mortalitas kardiovaskuler pada 55% yang disesuaikan untuk kategori diabetes melitus dan usia (HR 0.45 (0.21-0.48), p = 0.044). [11] Berdasarkan studi yang dilakukan oleh Seung Jin Han (2015), didapatkan hasil bahwa PTX secara signifikan dapat mengurangi kadar hemoglobin A1c (HbA1c), kadar gula darah puasa (fasting glucose level), dan HOMA-IR dibandingkan dengan kelompok placebo (p< 0.05). Dalam studi ini juga dilakukan analisis multivariat regresi untuk melihat efek dari PTX terhadap penurunan kadar glukosa.…”

Section: Artikel Tinjauan Pustakaunclassified

“…Pentoxifylline Terhadap Mortalitas Kardiovaskular. [11] Tabel 3. Tabel yang Menujukkan Perbandingan Variabel yang Diteliti Antara Kelompok Kontrol dan Kelompok yang Mendapat Terapi Pentoxifylline.…”

Section: Gambar 5 Grafik Yang Menunjukkan Efekunclassified

See 3 more Smart Citations

Penthoxyfilline Sebagai Terapi Komplementer Chronic Kidney Disease

Widianantara¹,

Dewi²,

Purwaningrum³

2021

ESSENTIAL

View full text Add to dashboard Cite

Chronic kidney disease (CKD) was the 18th most common death cause annually, that often associated with elderly, diabetes, hypertension, obesity, and cardiovascular disease. CKD treatment that available now deemed less effective because it only postpone the progression od the disease. Pentoxyfilline (PTX) was one of treatment that can be used as complementary therapy in CKD. PTX can deliver renoprotective effect. Also, it can resolve proteinuria problem in patient with diabetic neuropathy. Therefore, PTX can be used as complementary therapy in patient with CKD

show abstract

Section: Pendahuluanunclassified

Section: Artikel Tinjauan Pustakaunclassified

Section: Gambar 5 Grafik Yang Menunjukkan Efekunclassified

See 2 more Smart Citations

Penthoxyfilline Sebagai Terapi Komplementer Chronic Kidney Disease

Widianantara¹,

Dewi²,

Purwaningrum³

2021

ESSENTIAL

View full text Add to dashboard Cite

show abstract

“…As well, pentoxifylline ameliorates renal tissue injury through anti-inflammatory and antioxidant effects. [1011]…”

Section: Introductionmentioning

confidence: 99%

Synergistic effect of berberine and pentoxifylline in attenuation of acute kidney injury

Al-Kuraishy

Al-Gareeb

Hussien

2019

Int J Crit Illn Inj Sci

View full text Add to dashboard Cite

Objective: To evaluate the renoprotective effects of berberine and/or pentoxifylline in reduction of diclofenac-induced acute kidney injury (AKI) in rats. Material and Methods: Fifty male Sprague-Dawley rats were allocated into five groups, Group 1: Rats treated with distilled water plus normal saline for 12 days. Group 2: Rats treated with distilled water plus diclofenac for 12 days. Group 3: Rats treated with berberine plus diclofenac for 12 days. Group 4: Rats treated with pentoxifylline plus diclofenac for 12 days. Group 5: Rats treated with berberine + pentoxifylline plus diclofenac 15 mg/kg for 12 days. Blood urea, creatinine, neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecules (KIM-1), and cystatin-c were used to measure the severity of AKI. Results: Diclofenac led to significant AKI by significant elevation of blood urea, serum creatinine, KIM-1, and NGAL. Treatment with berberine showed no significant effect on all biomarkers level compared to diclofenac group except on serum KIM-1 level which also seen in the pentoxifylline group whereas combination of berberine and pentoxifylline led to more significant effect in the reduction of all renal biomarkers. Conclusion: Combination of berberine with pentoxifylline illustrated a synergistic effect in attenuation of diclofenac-induced AKI.

show abstract